Ikena Oncology, Inc. (IKNA)
$
1.4
-0.05 (-3.57%)
Key metrics
Financial statements
Free cash flow per share
-0.7929
Market cap
70 Million
Price to sales ratio
0
Debt to equity
0.0559
Current ratio
13.3059
Income quality
0.9174
Average inventory
0
ROE
-0.3200
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Ikena Oncology, Inc. is a targeted oncology company focused on developing medicines tailored to biomarker-defined patient groups addressing specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain transcription factor in the Hippo signaling pathway. Additionally, it is advancing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of the aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist designed for treating microsatellite stable colorectal cancer. The diluted EPS is -$1.02 accounting for potential share dilution. The total costs and expenses for the company are $0.00 reflecting its overall spending. The earnings per share (EPS) is reported at -$1.02 indicating the company's profitability on a per-share basis. The EBITDA ratio is $0.00 highlighting the company's operational efficiency. Moreover, the operating expenses amount to $58,973,000.00 encompassing various operational costs incurred. In terms of financial accessibility, the stock is affordable at $1.40 making it suitable for budget-conscious investors. The stock features a low average trading volume of 99,582.00 indicating lower market activity. With a market capitalization of $67,561,340.00 the company is classified as a small-cap player. It plays a significant role in the Biotechnology industry, contributing greatly to the overall market landscape. Furthermore, it belongs to the Healthcare sector, driving innovation and growth within the field. These elements combine to position Ikena Oncology as a crucial player in targeted oncology, working towards addressing significant health challenges.
Is Ikena Oncology, Inc. (IKNA) a good investment?
Investing in Ikena Oncology, Inc. (IKNA) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bullish outlook. Always conduct your own research before investing.
What is Ikena Oncology, Inc. (IKNA)'s stock forecast?
Analysts predict Ikena Oncology, Inc. stock to fluctuate between $0.97 (low) and $1.94 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Ikena Oncology, Inc.'s market capitalization?
As of 2025-06-11, Ikena Oncology, Inc.'s market cap is $67,561,340, based on 48,258,100 outstanding shares.
How does Ikena Oncology, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Ikena Oncology, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Ikena Oncology, Inc. (IKNA) stock?
To buy Ikena Oncology, Inc. (IKNA) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for IKNA. Place an order (Market, Limit, etc.).
What is the best time to invest in Ikena Oncology, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Ikena Oncology, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$1.02 | Growth: -37.42%.
Where can I find Ikena Oncology, Inc.'s investor relations reports?
Visit https://ikenaoncology.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Ikena Oncology, Inc.?
You can explore historical data from here
What is the all-time high and low for Ikena Oncology, Inc. stock?
All-time high: $37.61 (2021-03-26) | All-time low: $0.97 (2025-04-09).
What are the key trends affecting Ikena Oncology, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
5 months ago
Ikena Oncology (IKNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
globenewswire.com
6 months ago
Inmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody with an extended half-life and a silenced ADCC function
globenewswire.com
6 months ago
Inmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody with an extended half-life and a silenced ADCC function
globenewswire.com
7 months ago
Strong financial position with $138 million in cash and investments at close of third quarter Strong financial position with $138 million in cash and investments at close of third quarter
globenewswire.com
10 months ago
Strong financial position with $145 million in cash and investments at close of second quarter Strong financial position with $145 million in cash and investments at close of second quarter
zacks.com
a year ago
IKNA, AVAH, and VEL made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 12, 2024.
zacks.com
a year ago
USAC, NHYDY, APOG, IKNA, and CRGY have been added to the Zacks Rank #1 (Strong Buy) List on July 12, 2024.
globenewswire.com
a year ago
Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Exploring strategic options to maximize shareholder value BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”) today announced discontinuation of the clinical IK-930 program, the Company's TEAD1- selective Hippo pathway inhibitor and continued clinical development of IK-595, a novel MEK-RAF molecular glue. Concurrently, Ikena is evaluating strategic options for both the Company and its development pipeline.
globenewswire.com
a year ago
Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Exploring strategic options to maximize shareholder value BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”) today announced discontinuation of the clinical IK-930 program, the Company's TEAD1- selective Hippo pathway inhibitor and continued clinical development of IK-595, a novel MEK-RAF molecular glue. Concurrently, Ikena is evaluating strategic options for both the Company and its development pipeline.
globenewswire.com
a year ago
Strong financial position with $157.3 million; runway into 2H 2026 IK-930 program on track to deliver clinical update in 2H 2024 IK-595 program continues dose escalation in patients with RAS and RAF mutant cancers BOSTON, May 13, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the first quarter ended March 31, 2024. The Company also provided an update regarding its organization and pipeline.
See all news
